A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.
Tran MC, Hasan Y, Wang A, Yenice K, Partouche J, Stock W, Larson RA, Kosuri S, LaBelle JL, Kline J, Riedell PA, Artz AS, Weichselbaum R, Bishop MR, Aydogan B, Liu H.
Tran MC, et al. Among authors: partouche j.
Blood Adv. 2023 Feb 14;7(3):285-292. doi: 10.1182/bloodadvances.2022007530.
Blood Adv. 2023.
PMID: 35851593
Free PMC article.
Clinical Trial.